You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

133 Results
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Adjuvant, Curative
New
Apr 2026
Regimen
Intent: Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
New
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
New
Apr 2026
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant, Adjuvant
New
Apr 2026
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
New
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
New
Apr 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
New
Apr 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Updated
Apr 2026
Guidelines and Advice
Status: Current
ID: 19-4
Version: 2
Updated
Mar 2026
Drug
Other Name(s): Lupron Depot® , Eligard®
Updated
Apr 2026
Drug
Other Name(s): Voranigo™
Updated
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide
Updated
Apr 2026

Pages